Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)835.00
  • Today's Change-3.00 / -0.36%
  • Shares traded609.17k
  • 1 Year change26.80%
  • Beta-0.0084
Data delayed at least 20 minutes, as of Apr 24 2019 16:35 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Apr 19, 2019, the consensus forecast amongst 10 polled investment analysts covering BTG plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 26, 2018. The previous consensus forecast advised that BTG plc would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy3
Outperform1
Hold5
Underperform1
Sell0

Share price forecast

The 9 analysts offering 12 month price targets for BTG plc have a median target of 840.00, with a high estimate of 840.00 and a low estimate of 490.00. The median estimate represents a 0.24% increase from the last price of 838.00.
High0.2%840.00
Med0.2%840.00
Low-41.5%490.00

Dividends

Historical dividend information is not available for BTG PLC.
Div growth (TTM)--
More ▼

Earnings history & estimates

On Nov 13, 2018, BTG plc reported semi annual 2019 earnings of 0.2775 per share. This result exceeded the 0.24 consensus of the 3 analysts covering the company and exceeded last year's results for the same period by 32.79%.
Average growth rate+80.92%
BTG plc reported annual 2018 earnings of 0.327 per share on May 15, 2018.
The next earnings announcement from BTG plc is expected the week of May 13, 2019.
Average growth rate+24.23%
More ▼

Revenue history & estimates

BTG plc reported semi annual 2019 revenues of 382.16m. This bettered the 361.69m consensus of the 3 analysts covering the company. This was 11.97% above the prior year's period results.
Average growth rate+9.57%
BTG plc had revenues for the full year 2018 of 620.50m. This was 8.76% above the prior year's results.
Average growth rate+21.13%
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.